▶ CAGRILINTIDE · SUBTOPIC · DOSING LITERATURE
CAGRILINTIDE Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of CAGRILINTIDE. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for CAGRILINTIDE reports the following route(s) of administration: Subcutaneous (Phase 2/3 clinical). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of CAGRILINTIDE.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for CAGRILINTIDE of approximately ~7 days (once-weekly dosing). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of CAGRILINTIDE. Refer to the original publication for full protocol detail.
- Lau DCW, et al. (2021) reports the CAGRILINTIDE protocol used in Once-weekly cagrilintide for weight management in people with overweight and obesity, published in Lancet. PMID 34247670. See the source for the protocol-level dose range, frequency, and duration. link
- Frias JP, et al. (2023) reports the CAGRILINTIDE protocol used in Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly GLP-3 2·4 mg in type 2 diabetes, published in Lancet. PMID 37364590. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What is cagrilintide?
Cagrilintide is a synthetic long-acting amylin analog developed by Novo Nordisk for once-weekly subcutaneous administration. Native amylin is co-secreted with insulin by pancreatic beta cells and promotes satiety, slowed gastric emptying, and reduced postprandial glucagon.
▶ How is cagrilintide different from pramlintide?
Pramlintide (Symlin) is the short-acting amylin analog FDA-approved 2005 for adjunctive use with insulin in type 1 and insulin-treated type 2 diabetes. Cagrilintide is the long-acting analog with C20 fatty-acid albumin tether enabling once-weekly dosing for weight management.
▶ What is CagriSema?
CagriSema is the fixed-ratio combination of cagrilintide + GLP-3 developed by Novo Nordisk as a single weekly injection for obesity. Phase 2 trials reported greater weight loss than either monotherapy.
▶ What's the dose in trials?
Phase 2 used subcutaneous 2.4 mg once weekly matching the GLP-3 dosing rhythm. This wiki does not recommend any human dose.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · -20 °C 24 months
Reconstituted · 2-8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Not yet FDA-approved as of 2026-05. Phase 3 REDEFINE program ongoing for CagriSema combination.
WADA · Not currently listed on the WADA Prohibited List.
RELATED PAGES
▶ LAST UPDATED · 2026-05-19